[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Badgwell BD, Valentino DJ, Jeffes EB, Dieffenbach K, Dulkanchainun SB, Yamamoto RS, Granger GA, Jakowatz JG, Carson WE: Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma. Cancer Immunol Immunother; 2003 Jan;52(1):10-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma.
  • The intra-arterial (IA) administration of TNF-alpha to patients with liver metastases represents one such approach, and recent work suggests that subsequent ablation of the tumor's arterial supply via embolization may enhance the efficacy of intra-arterial treatments (hepatic chemoembolization).
  • The present study was undertaken to test the hypothesis that IA administration of TNF-alpha is superior to the intravenous (IV) route for inhibition of tumor growth in a regionally confined rat mammary adenocarcinoma model that provides for ablation of the arterial supply to the tumor following cytokine therapy.
  • Control animals received either no treatment or IA infusion of 2% normal rat serum (NRS) followed by ipsilateral CFA ligation.
  • Tumor size was measured every other day after treatment.
  • Tumor growth inhibition occurred in the first 5 to 10 days after treatment.
  • IA administration of TNF-alpha resulted in statistically significant diminution of tumor size as compared to untreated controls and animals receiving IA 2% normal rat serum (NRS; P<0.05 at days 6, 8 and 10), regardless of the dose employed.
  • IA administration of biologic response modifiers like TNF-alpha may therefore be a useful approach for the hepatic chemoembolization of breast adenocarcinomas metastatic to the liver.
  • [MeSH-major] Adenocarcinoma / drug therapy. Femoral Artery / surgery. Immunologic Factors / therapeutic use. Mammary Neoplasms, Experimental / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Hindlimb. Infusions, Intravenous. Injections, Intra-Arterial. L Cells (Cell Line) / drug effects. Ligation. Mice. Neoplasm Transplantation. Rats. Rats, Inbred F344. Recombinant Proteins / therapeutic use. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / transplantation

  • COS Scholar Universe. author profiles.
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12536235.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86016; United States / NCI NIH HHS / CA / P30 CA16058
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


2. Levi M, DeRemer SJ, Dou C, Ensminger WD, Smith DE: Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine. Biopharm Drug Dispos; 2004 Jan;25(1):27-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
  • PURPOSE: Amifostine is a prodrug in which selectivity is largely determined by the preferential formation and uptake of its cytoprotective metabolite, WR-1065, in normal tissues as a result of differences in membrane-bound alkaline phosphatase activity.
  • It was hypothesized that amifostine may be a good candidate for regional drug delivery to the liver because of its large hepatic extraction and total body clearance.
  • METHODS: Rat livers were implanted with Walker-256 tumors.
  • WR-1065 concentrations in the blood, liver and tumor were measured at various times.
  • The portal dosing WR-1065 liver AUC15-60 was 60% higher than the values for systemic dosing.
  • The liver/tumor concentration ratios of WR-1065 following portal dosing were up to 8-fold higher than the ratio following systemic administration.
  • CONCLUSIONS: Amifostine may provide increased liver protection and decreased tumor protection from radio- or chemotherapy when administered by the portal vein.
  • [MeSH-major] Amifostine / administration & dosage. Amifostine / metabolism. Drug Delivery Systems / methods. Liver Neoplasms, Experimental / drug therapy. Mercaptoethylamines / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / surgery. Disease Models, Animal. Drug Screening Assays, Antitumor. Femoral Vein / drug effects. Infusions, Intravenous. Male. Neoplasm Transplantation / methods. Portal Vein / drug effects. Prodrugs / administration & dosage. Prodrugs / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 John Wiley & Sons, Ltd.
  • (PMID = 14716750.001).
  • [ISSN] 0142-2782
  • [Journal-full-title] Biopharmaceutics & drug disposition
  • [ISO-abbreviation] Biopharm Drug Dispos
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098502
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mercaptoethylamines; 0 / Prodrugs; 31098-42-7 / WR 1065; M487QF2F4V / Amifostine
  •  go-up   go-down


3. Hribaschek A, Ridwelski K, Pross M, Meyer F, Kuhn R, Halangk W, Boltze C, Lippert H: Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model. Oncol Rep; 2003 Nov-Dec;10(6):1793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model.
  • Currently, there are no established protocols for the treatment or prevention of peritoneal carcinomatosis.
  • as late intraperitoneal (i.p.) chemotherapy (15, 20, 25 days following surgery; aiming for reduction of a manifest peritoneal carcinomatosis; group C) into the abdominal cavity.
  • Tumor growth was quantified by tumor weight of the greater omentum and the mesenteric site, number of detectable tumor lesions, occurrence of hepatic and pulmonary metastases and the amount of ascites.
  • Taxol was highly effective in preventing or reducing i.p. tumor spread when the drug was given directly or within a short time interval after tumor cell implantation (groups A and B), whereas no significant antineoplastic potential was found in the treatment of an established peritoneal carcinomatosis.
  • [MeSH-major] Carcinoma / drug therapy. Paclitaxel / therapeutic use. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Animals. Antineoplastic Agents, Phytogenic / therapeutic use. Cell Division. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Disease Models, Animal. Humans. Infusions, Parenteral. Lung / pathology. Neoplasm Metastasis. Neoplasm Transplantation. Rats

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534698.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Li FR, Yan WH, Guo YH, Qi H, Zhou HX: Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer. Int J Hyperthermia; 2009 Aug;25(5):383-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer.
  • It is suitable to various types of tumors.
  • The purpose of this study was to prepare carboplatin-Fe@C-loaded chitosan nanoparticles with Fe@C as a magnetic core and to investigate efficacy of hyperthermia combined with chemotherapy for transplanted liver cancer in rats.
  • The shape, size, drug-loading rate, and in vitro cumulative release of the nanoparticles were observed and heat product under high frequency alternating electromagnetic field in vitro was explored.
  • Eighty rats with transplanted liver cancer were randomly divided into 4 groups (group A: control group, group B: free carboplatin group, group C: nanoparticles with static magnetic field group, and group D: nanoparticles with static field and alternating magnetic field).
  • Drug was injected into the hepatic artery.
  • The therapeutic effect of hyperthermia combined with chemotherapy for tumor, toxicity and rat survival time were observed.
  • The drug-loading rate of the nanoparticles was 11.0 +/- 1.1%.
  • The cumulative release percentage of carboplatin-Fe@C-loaded chitosan nanoparticles in vitro at different point time phase of 24 h, 48 h, 72 h, 96 h and 120 h were 51%, 68%, 80%, 87% and 91%, respectively.
  • In vivo experiments showed that after particle injection, tumor temperature reached 42.6 degrees +/- 0.2 degrees C within 10 min in the alternating magnetic field; and the temperatures in the right hepatic lobes and the rectum were significantly lower than in the tumor and the constant temperature could last up to 30 min.
  • The inhibition ratio of tumor weight in group D was significantly enhanced, no obviously toxic and side-effect occurred and survival time was prolonged.
  • They can target liver cancer tissue by static magnetic field, and with the application of alternating magnetic field, effectively raise tumor tissue temperature and facilitate tumor apoptosis.
  • The combination of chemotherapy and magnetic materials into nanoparticles as described herein demonstrates promising efficacy.
  • [MeSH-major] Carboplatin / therapeutic use. Chitosan / therapeutic use. Ferric Compounds / therapeutic use. Liver Neoplasms / therapy. Nanoparticles / therapeutic use
  • [MeSH-minor] Animals. Combined Modality Therapy. Hyperthermia, Induced / methods. Magnetics. Neoplasm Transplantation. Rats

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391033.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ferric Compounds; 9012-76-4 / Chitosan; BG3F62OND5 / Carboplatin
  •  go-up   go-down


5. Jäger W, Salamon A, Szekeres T: Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. Curr Med Chem; 2002 Apr;9(7):781-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent study demonstrates enzymatic deamination of BR to non-cytotoxic benzene carboxylic acid (BR-COOH) as the main hepatic BR biotransformation product in rat liver.
  • As the IMPDH inhibitors tiazofurin and ribavirin exhibit predominant accumulation and biotransformation in liver, hepatic metabolism may be an important factor also for BR activation and inactivation and should be considered in human liver during cancer therapy when BR is used as a single drug or in combination with other anticancer agents.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm. Forecasting. Humans. Isoenzymes / antagonists & inhibitors. K562 Cells. Liver / drug effects. Rats. Ribavirin / analogs & derivatives. Ribavirin / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11966442.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Isoenzymes; 0 / Nucleosides; 138385-29-2 / 3-(1-deoxyribofuranosyl)benzamide; 49717AWG6K / Ribavirin; EC 1.1.1.205 / IMP Dehydrogenase; ULJ82834RE / tiazofurin
  • [Number-of-references] 30
  •  go-up   go-down


6. Seelig MH, Leible M, Sänger J, Berger MR: Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence. Oncol Rep; 2004 May;11(5):1107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.
  • An orthotopic, isogenic rat model was used to determine the potential of chemoembolization (CHE) for reducing the tumor cell load of a diffusely metastatic liver.
  • Seven days after injecting CC531-lac-Z cells intraportally to male WAG/Rij rats, tumor positive animals were treated by injection into the hepatic artery with solvent (n=17), degradable starch microspheres (DSM, 30 mg/kg; n=16), DSM plus 5-fluorouracil (5-FU, dosages: 90, 60, and 40 mg/kg) or DSM plus gemcitabine (Gem, dosages: 100, 80, 50, and 10 mg/kg).
  • After 3 more weeks the experiment was terminated, the livers were weighted and the number of CC531-lac-Z cells per liver was determined.
  • In summary, the comparison of CHE with 5-FU or Gem shows that the efficacy of Gem in reducing the hepatic tumor cell load was significantly higher and its therapeutic ratio was greater than that of 5-FU.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Chemoembolization, Therapeutic. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Animals. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Disease Models, Animal. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Male. Microspheres. Neoplasm Transplantation. Organ Size. Rats. Rats, Inbred Strains. Tumor Burden

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069554.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Moran DM, Mayes N, Koniaris LG, Cahill PA, McKillop IH: Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int; 2005 Apr;25(2):445-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
  • BACKGROUND: Interleukin-6 (IL-6) plays a critical role in normal hepatic growth and liver regeneration.
  • METHODS: An in vivo rat HCC model was established and IL-6 receptor (IL-6R) and downstream signaling pathway expression and activity were determined in HCC and normal liver specimens.
  • RESULTS: HCC specimens demonstrated decreased IL-6Ralpha/gp130 expression as compared with the normal liver.
  • IL-6 treatment of HCC cells inhibits serum-stimulated mitogenesis, possibly via differences in activation profiles of intracellular signaling pathways and their effect on CDK inhibitor expression/activity.
  • [MeSH-major] Cell Proliferation / drug effects. DNA-Binding Proteins / metabolism. Hepatocytes / cytology. Interleukin-6 / metabolism. Receptors, Interleukin-6 / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Animals. Base Sequence. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Disease Models, Animal. Liver Neoplasms, Experimental. Male. Mitogen-Activated Protein Kinase 3 / metabolism. Molecular Sequence Data. Probability. RNA, Neoplasm / analysis. Random Allocation. Rats. Rats, Inbred ACI. Reverse Transcriptase Polymerase Chain Reaction. STAT3 Transcription Factor. Sensitivity and Specificity. Signal Transduction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005
  • [CommentIn] Liver Int. 2006 Oct;26(8):1018-9 [16953844.001]
  • (PMID = 15780071.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA90895
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Interleukin-6; 0 / RNA, Neoplasm; 0 / Receptors, Interleukin-6; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 0 / Trans-Activators; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


8. Huang Z, Waxman DJ: Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther; 2001 Jun;8(6):450-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
  • This gene therapy strategy provides for intratumoral prodrug activation, but is also associated with a high level of hepatic prodrug activation, which reduces the extent of intratumoral prodrug activation and contributes to systemic drug toxicity.
  • To address this issue, five P450 inhibitors were tested for their ability to block liver CYP2C-catalyzed CPA activation selectively, i.e., without inhibiting the corresponding intratumoral activation of CPA catalyzed by a transduced CYP2B enzyme.
  • In vitro studies revealed that the P450 inhibitors 1-aminobenzotriazole and DDEP were preferentially inhibitory toward CYP2C-dependent liver microsomal CPA activation, whereas the P450 inhibitor SKF-525A inhibited CYP2C- and CYP2B-dependent CPA activation without P450 form selectivity.
  • Rat pharmacokinetic studies confirmed the inhibitory action of these compounds in vivo, with up to a 4-fold decrease in C(max) and a 7-fold increase in apparent half-life of the activated CPA metabolite, 4-hydroxy-CPA, seen in the case of 1-aminobenzotriazole.
  • Although the rate of hepatic CPA activation could thus be decreased substantially by P450 inhibitor treatment, the net extent of hepatic CPA activation was only modestly decreased, as judged by plasma area-under-the-curve values for 4-hydroxy-CPA.
  • Moreover, P450 inhibitor treatment did not decrease CPA's host toxicity and did not enhance the tumor growth delay response to CPA in rats bearing CYP2B1-transduced gliosarcomas.
  • These findings are discussed in the context of P450-based gene therapy strategies and ongoing efforts to enhance anticancer drug activity by increasing the exposure of P450-expressing tumors to the P450-activated prodrug CPA.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacokinetics. Cyclophosphamide / pharmacokinetics. Cytochrome P-450 Enzyme Inhibitors. Cytochrome P-450 Enzyme System / genetics. Genetic Therapy / methods. Liver / enzymology
  • [MeSH-minor] Animals. Body Weight / drug effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Enzyme Activation. Male. Metyrapone / pharmacology. Neoplasm Transplantation. Neoplasms / drug therapy. Neoplasms, Experimental / drug therapy. Rats. Rats, Inbred F344. Time Factors

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11498765.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA49248
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cytochrome P-450 Enzyme Inhibitors; 8N3DW7272P / Cyclophosphamide; 9035-51-2 / Cytochrome P-450 Enzyme System; ZS9KD92H6V / Metyrapone
  •  go-up   go-down


9. Rodenbach M, Eyol E, Seelig MH, Berger MR: Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine. J Cancer Res Clin Oncol; 2005 May;131(5):289-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
  • PURPOSE: The aim of this study was to evaluate the combination effect of pemetrexed disodium (MTA; Alimta; LY 231514) and gemcitabine (GEM) administered by hepatic artery and portal vein chemoembolization (HACE and PVCE) in a colorectal cancer rat liver metastasis model.
  • MATERIALS AND METHODS: Proliferation studies on CC531-lac-Z rat colon cancer cells were performed using the MTT assay to obtain the optimal combination schedule of the two antineoplastic agents.
  • To generate diffuse liver metastasis, 4 x 10(6) tumor cells were implanted into the portal vein of male WAG/Rij rats.
  • GEM (50 mg/kg) was also given locoregionally by hepatic artery chemoembolization (HACE) as well as systemically.
  • Efficacy of treatment in terms of liver metastases burden was determined at the end of the experiment by measuring the beta-galactosidase activity of CC531-lac-Z cells with a chemoluminescence assay.
  • Simultaneous drug exposure showed less than additive combination effects (O/E ratios > or = 1.25).
  • In vivo, locoregional administration by HACE with GEM was significantly more effective than systemic intravenous bolus treatment (P = 0.03).
  • Repeated systemic treatment with MTA yielded a slight reduction in tumor cell load that was significant versus control at the medium and high doses (60 mg/kg, P = 0.009; 90 mg/kg, P = 0.046) but not versus intraportal chemoembolization.
  • The combination treatment of systemic (60 and 90 mg/kg) or locoregional (60 mg/kg) MTA with HACE using GEM (50 mg/kg) resulted in more than 80% tumor growth inhibition; this antineoplastic combination effect was maximally additive.
  • CONCLUSION: A regimen-dependent synergistic combination effect of both drugs was found in vitro.
  • In animals, hepatic artery chemoembolization with GEM was superior to systemic intravenous bolus treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Glutamates / therapeutic use. Guanine / analogs & derivatives. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Chemoembolization, Therapeutic. Colorectal Neoplasms. Combined Modality Therapy. Death. Disease Models, Animal. Male. Neoplasm Metastasis. Pemetrexed. Rats. Rats, Inbred Strains

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1990 Mar;159(3):325-9 [2305941.001]
  • [Cites] Surgery. 1974 Apr;75(4):589-96 [4840805.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii13-6 [12810452.001]
  • [Cites] Invasion Metastasis. 1993;13(2):102-12 [8225852.001]
  • [Cites] Radiology. 1993 Nov;189(2):417-22 [8210369.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):770-5 [9221850.001]
  • [Cites] Clin Exp Metastasis. 1999 Jul;17(5):369-76 [10651303.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3 [12023793.001]
  • [Cites] Clin Exp Metastasis. 2000;18(4):281-9 [11448057.001]
  • [Cites] Hepatology. 2003 Aug;38(2):295-304 [12883473.001]
  • [Cites] Proc Soc Exp Biol Med. 1965 Feb;118:465-8 [14268654.001]
  • [Cites] Acta Oncol. 1991;30(3):309-13 [2036239.001]
  • [Cites] Lung Cancer. 2001 Dec;34 Suppl 4:S103-5 [11742712.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):243-9 [10437612.001]
  • [Cites] Lab Anim Sci. 1999 Apr;49(2):216-9 [10331554.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii3-5 [12810450.001]
  • [Cites] Rev Prat. 2004 Jan 31;54(2):167-76 [15086059.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Apr;130(4):203-10 [14740207.001]
  • [Cites] Br J Surg. 1989 Jun;76(6):545-8 [2474356.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):1023-33 [11978527.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):100-5 [14981587.001]
  • [Cites] Oncol Rep. 2004 May;11(5):1107-13 [15069554.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1016-23 [10741729.001]
  • [Cites] Am J Pathol. 1954 Sep-Oct;30(5):969-77 [13197542.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):988-94 [1913493.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(1):42-6 [2936747.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4276s-4280s [15217974.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):233-9 [11801564.001]
  • [Cites] Clin Exp Metastasis. 2000;18(2):189-96 [11235995.001]
  • [Cites] Surg Endosc. 2000 May;14(5):448-51 [10858469.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1748-57 [10764436.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):158-69 [10100781.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1250-9 [9529016.001]
  • [Cites] Acta Oncol. 2001;40(2-3):282-308 [11441937.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3671-6 [10446980.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):163-73 [10962525.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):305-12 [11379296.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Nov;129(11):655-61 [14513367.001]
  • [Cites] Acta Oncol. 1987;26(5):361-5 [3426848.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5439-46 [15328182.001]
  • (PMID = 15657768.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Treshchalina EM, Andronova NV, Kobliakov VA, Raĭkhlin NT: [New models of experimental chemotherapy of tumors]. Vopr Onkol; 2001;47(6):701-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New models of experimental chemotherapy of tumors].
  • New neoplastic models such as orthotopic solitary hepatic tumor (cholangiocellular cancer PC-1) as well as different strains of malignant pleuritis (hemoblastosis and ascitic tumors) have been evolved by transplanting tumor cell suspension to rat liver or murine pleural cavity.
  • Orthotopic hepatic tumor PC-1 may be used for evaluating systemic and regional therapy.
  • Models of tumorous pleuritis described with respect to their response to chemotherapy, may have an application in screening and preclinical examination of newly-developed antitumor drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Drug Evaluation, Preclinical. Leukemia, Experimental / drug therapy. Liver Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Liver / pathology. Mice. Neoplasm Transplantation. Rats. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826492.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X: Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol; 2003 Nov;9(11):2445-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study.
  • METHODS: Male Wistar rats were inoculated with Walker-256 tumor in the left lobe of liver.
  • Normal saline, 5-Fu, 5-Fu and lipiodol were infused through hepatic artery respectively.
  • MVD of the control group, chemotherapy group and chemoemoblization group was 80.84+/-24.24, 83.05+/-20.29 and 85.20+/-23.91 (F=0.193, P=0.873), respectively.
  • CONCLUSION: There has been little influence of lipiodol chemoembolization on the formation of tumor angiogenesis, but the development of neovascularization and expression of VEGF play important roles in establishment of collateral circulation and reconstruction of blood supply of residual cancer tissue.
  • [MeSH-major] Carcinoma 256, Walker / physiopathology. Chemoembolization, Therapeutic. Fibroblast Growth Factor 2 / metabolism. Liver Neoplasms, Experimental / physiopathology. Neovascularization, Pathologic / therapy. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Animals. Immunohistochemistry. Male. Microcirculation. Neoplasm Transplantation. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14606073.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC4656518
  •  go-up   go-down






Advertisement